drugset / Trial / NCT04391556

Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma

NCT04391556

Phase 2 Completed 57 enrolled Centre Leon Berard
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treatment

Timeline

Start
2020-09-14
Primary completion
2023-05-02
Completion
2024-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 120 mg Subcutaneous